Trial Profile
Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Kyowa Hakko Kirin China Pharmaceutical
- 01 Mar 2022 Results assessing Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim published in the Clinical Pharmacology in Drug Development
- 11 Oct 2017 Status changed from recruiting to completed.
- 26 Apr 2016 New trial record